MUC1 568 A/G genotype-dependent Cancer Antigen 15-3 levels in breast cancer patients |
| |
| Authors: | Adrian Kruit Madeleine M Tilanus-Linthorst Joke G Boonstra Ron HN van Schaik Jan C Grutters Jules MM van den Bosch Henk JT Ruven |
| |
| Institution: | 1. First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan;2. Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan;3. Department of Respiratory Medicine, JR Sapporo Hospital, Sapporo, Japan;1. Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China;2. Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou, China;3. Department of Radiation Oncology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China;4. Department of Internal Medicine, Cancer Center, Sun Yat-sen University, Guangzhou, China;5. Division of Nephrology, Department of Internal Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China;6. Key Laboratory of Tropical Diseases and Control of the Ministry of Education, Guangzhou, China |
| |
| Abstract: | ObjectivesCA 15-3 is a widely used tumor marker for breast cancer. We have investigated whether the MUC1 568 A/G polymorphism can influence CA 15-3 levels in healthy women and patients with breast tumors.Design and methodsCA 15-3 was measured in 208 healthy women, in 67 with benign disease, and in 162 women with breast cancer. All subjects were genotyped for the MUC1 568 A/G polymorphism.ResultsSignificant differences were observed between mean CA 15-3 levels of control subjects grouped according to the MUC1 568 genotype (mean ± SD): AA (10.3 ± 3.8), AG (15.9 ± 5.0) and GG (19.0 ± 5.6) U/mL, p < 0.0001. Similar (median) results were observed in women with benign breast disease: AA (10.2), AG (14.2) and GG (16.6) U/mL, p < 0.0001, and those with breast cancer: AA (10.4), AG (17.1) and GG (23.9) U/mL, p < 0.0001.ConclusionsThe MUC1 568 A/G polymorphism strongly influences CA 15-3 levels in healthy women and women with either benign or malignant breast tumors. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
